Notifications
Back
Therapeutic Organoid Intelligence,
Engineered to Power the Longevity Revolution. 

We do not settle for cutting-edge — We define it.

We don’t just extend life — we reinvent how we live it.


Therapeutic Organoid Intelligence, Engineered to Power the Longevity Revolution. 

We do not settle for cutting-edge — We define it.
We don’t just extend life — we reinvent how we live it.

Core Values

CELLinCELLS is a regenerative medicine company dedicated to extending healthy and happy lives

"Regenerative Longevity"

Business

CELLinCELLS, Therapeutic Organoid Platform Tech Company

mobile background

TRTP
Tissue-Reforming Technology Platform

The 3D Tissue-Reforming Technology Platform(TRTP) an innovative technology for creating organoid tissue modules, serving as a platform for developing high-quality organoid regenerative therapies.

Pipeline

Introducing CELLinCELLS' flagship pipeline.

Competitive Advantage

CELLinCELLS' Unique Competitive Advantage


Core Technology Competitiveness

01. Purely Domestic Organoid Production Core Platform

02. Unique Organoid-Tissue Module Manufacturing Method : The method features a concave cup-shaped structure, allowing for smooth nutrient and oxygen supply to the center, overcoming the limitations of organoid size.

03. AI Deep Learning-Based Organoid Production Prediction and Evaluation Technology

Manufacturing Technology Capabilities

01. Purely Domestic Organoid Production Core Platform

02. Cell Bank Construction Technology 

Clinical Status
 (Atrophic Scar Skin Regenerative Therapy)

01. 2023 IND Approval > Administration Completed in 2024

02. Significant Superiority Confirmed Compared to Preceding Drugs

03. Clinical Results Report and Presentation at Relevant Conferences in Q1 2025 

Core Values

Development of new-modality regenerative medicine based on innovative technology that goes beyond first-in-class

" Regenerative Longevity "

Business

CELLinCELLS, Therapeutic Organoid Platform Tech Company

mobile background

Core Technology

The 3D Tissue-Reforming Technology Platform(TRTP) is

an innovative technology for creating organoid tissue modules,

serving as a platform for developing high-quality organoid regenerative therapies.

Pipeline

Introducing CELLinCELLS' flagship pipeline.

Competitive Advantage 

CELLinCELLS' Unique Competitive Advantage 


Core Technology Competitiveness
01. 
Purely Domestic Organoid Production Core Platform
02.
Unique Organoid-Tissue Module Manufacturing Method
: The method features a concave cup-shaped structure, allowing for smooth nutrient and oxygen supply to the center, overcoming the limitations of organoid size.
03.
AI Deep Learning-Based Organoid Production Prediction and Evaluation Technology
01. 
Purely Domestic Organoid Production Core Platform
02.
Cell Bank Construction Technology
Manufacturing Technology Capabilities 
Clinical Status
 (Atrophic Scar Skin Regenerative Therapy)
01. 
2023 IND Approval > Administration Completed in 2024
02.
Significant Superiority Confirmed Compared to Preceding Drugs
03.
Clinical Results Report and Presentation at Relevant Conferences in Q1 2025 

Head Office             

2nd Floor, Room 203, 240-39 Changgyeonggung-ro, Jongno-gu, Seoul, South Korea (Gwangwon Building, Myeongnyun 4-ga)

TEL  +82-2-742-0032   FAX  +82-2-764-7300

Yeongeon Office             

Room 501, Biomaterials Research Building, 101 Daehak-ro, Jongno-gu, Seoul, South Korea (Seoul National University School of Dentistry)

TEL  +82-2-740-8641   FAX  +82-2-742-8666

Munjeong Office             

Room 523, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea (Teratower, Munjeong Station)

TEL  +82-2-742-0032   FAX  +82-2-764-7300

Corporate Research Institute             

Rooms 513–515, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea (Teratower, Munjeong Station)

TEL  +82-2-742-0032   FAX  +82-2-764-7300

Copyrights © 2025 CELLinCELLS. All Rights Reserved.
Yeongeon Office   

Room 501, Biomaterials Research Building, 101 Daehak-ro, Jongno-gu, Seoul, South Korea
(Seoul National University School of Dentistry)    

TEL  +82-2-740-8641     

FAX  +82-2-742-8666

Munjeong Office   

Room 523, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea
(Teratower, Munjeong Station)   

TEL  +82-2-742-0032

FAX  +82-2-764-7300

Corporate Research Institute   

Rooms 513–515, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea
(Teratower, Munjeong Station)    

TEL  +82-2-742-0032     

FAX  +82-2-764-7300

E-Mail  

office@cellincells.com

Copyrights © 2025 CELLinCELLS co.,Ltd. All Rights Reserved.